Biotech
-
Roivant strikes broad pipeline pact with Daiichi
Roivant has secured an choice to license a stream of medication from Daiichi Sankyo. The deal is the primary time…
Read More » -
International Isotopes Inc. (OTCBB:INIS) is Attracting Smart Money
In a simply printed Form 13, filed with the US Securities and Exchange Commission (SEC), International Isotopes Inc. (OTCBB:INIS) reported that…
Read More » -
Communique from EGM in Oncology Venture A/S Stockholm Stock Exchange:OV
Company Announcement Communique from EGM in Oncology Venture A/S Hoersholm, Denmark, December 18, 2018 – at this time, a…
Read More » -
Chugai preps filings for IL-6 drug in rare disease, chasing Soliris
Chugai has the optimistic part 3 knowledge it must file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum dysfunction…
Read More » -
Here’s Who Just Picked Up Photomedex Inc (NASDAQ:PHMD) Shares
In a simply revealed Form 13, filed with the US Securities and Exchange Commission (SEC), Photomedex Inc (NASDAQ:PHMD) reported that…
Read More » -
DBV pulls peanut allergy filing after FDA faults data details
DBV Technologies has withdrawn the filing for FDA approval of its peanut allergy remedy. The French biotech pulled the BLA…
Read More » -
Cara Therapeutics Continues to Climb (NASDAQ:CARA)
We suppose Cara Therapeutics (NASDAQ: CARA), a boutique “clinical stage” biotech/biopharma firm which develops novel compounds (together with hashish derived…
Read More » -
The Right Way to Address Prescription Drug Costs
Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to define…
Read More » -
NRC Health Trends Report Uncovers the Forces Shaping Healthcare Consumerism Nasdaq:NRC
LINCOLN, Neb., Dec. 21, 2018 (GLOBE NEWSWIRE) — NRC Health, the main supplier of in-depth buyer intelligence in healthcare, at…
Read More » -
G1 tanks after placebo beats drug in cancer response rate test
G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo towards a number of efficacy measures in section 2. Trilaciclib…
Read More »